Evaluation of an enhanced service for medication review with follow up in Swiss community pharmacies: Pre-post study protocol.

Background: In Switzerland, 20,000 people are hospitalized each year as result of drug related problems (DRPs). The sources of DRPs can be related to patients' behavior (i.e.

Documentation of drug related problems and their management in community pharmacy: Data evolution over six years.

Background: Documentation of pharmacists' activities, such as drug related problems (DRPs) management, is necessary to estimate fair remuneration but is rarely done in community pharmacies.

Objective: To document and evaluate the evolution of DRPs prevalence and management over six years.

Methods: Observational study carried out since 2016 in a community pharmacy.

Domiciliary medication review (ReMeDo): development, reliability and acceptability of a tool for community pharmacists.

Objectives: Polymedication and medication hoarding in patients' homes may increase the risk of drug-related problems (DRPs). Community pharmacists can prevent DRPs through medication reconciliation and review. This study aims to (1) develop a tool for community pharmacists to perform domiciliary medication review (ReMeDo) and (2) assess the interrater and test-retest reliability and acceptability of the tool.

Clinical Pharmacy Activities Documented (ClinPhADoc): Development, Reliability and Acceptability of a Documentation Tool for Community Pharmacists.

Documentation of community pharmacists' clinical activities, such as the identification and management of drug-related problems (DRPs), is recommended. However, documentation is not systematic in Swiss community pharmacies, and relevant information about DRPs, such as consequences or involved partners, is frequently missing. This study aims to evaluate the interrater and test-retest reliability, appropriateness and acceptability of the Clinical Pharmacy Activities Documented (ClinPhADoc) tool.

Beliefs influencing community pharmacists' interventions with chronic kidney disease patients: A theory-based qualitative study.

Background: Drug-related problems (DRPs) are highly prevalent in chronic kidney disease (CKD) patients. Community pharmacists are ideally positioned to manage these DRPs. However, little is known about the factors influencing their interventions with CKD patients.

Prevalence and Management of Drug-Related Problems in Chronic Kidney Disease Patients by Severity Level: A Subanalysis of a Cluster Randomized Controlled Trial in Community Pharmacies.

Background: Drug-related problems (DRPs) are prevalent among chronic kidney disease (CKD) patients. However, little is known about their severity and management by community pharmacists.

Objectives: To (a) describe the prevalence of DRPs by severity level in CKD patients and (b) assess the effect of a training-and-communication network program in nephrology (ProFiL) on these DRPs.

Community Pharmacist Training-and-Communication Network and Drug-Related Problems in Patients With CKD: A Multicenter, Cluster-Randomized, Controlled Trial.

Background: Appropriate training for community pharmacists may improve the quality of medication use. Few studies have reported the impact of such programs on medication management for patients with chronic kidney disease (CKD).

Study Design: Multicenter, cluster-randomized, controlled trial.

Development and validation of criteria for classifying severity of drug-related problems in chronic kidney disease: A community pharmacy perspective.

Purpose: The development and validation of criteria for classifying severity of drug-related problems (DRPs) in chronic kidney disease (CKD) in the community pharmacy setting are described.

Methods: The Severity Categorization for Pharmaceutical Evaluation (SCOPE) criteria were adapted from an existing tool based on the interventions required to manage DRPs in community pharmacy. Ten community pharmacists reviewed the criteria.

Development and validation of the PAIR (Pharmacotherapy Assessment in Chronic Renal Disease) criteria to assess medication safety and use issues in patients with CKD.

Background: Explicit criteria for judging medication safety and use issues in patients with chronic kidney disease (CKD) are lacking.

Study Design: Quality improvement report.

Setting & Participants: Nephrologists (n = 4), primary care physicians (n = 2), hospital pharmacists with expertise in nephrology (n = 4), and community pharmacists (n = 2).